Metraipolis › archive › dc_5b08efb3fc7b

Preliminary Cost-Effectiveness of Re-Purposing β-Blockers as an Adjunct Treatment for Women with Triple-Negative Breast Cancer — Europe PMC PMID:41302317

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41302317
DOI
10.3390/healthcare13222929
License (as archived)
solo-consultazione
Archived
2026-11-08T13:10:02.164Z
SHA-256 of the archived text
c0481ed5d0bedc63b3e077593cbb1c483032472747af8f0341d1683207d99d84
Stable URL of this page
https://metraipolis.com/documento/dc_5b08efb3fc7b

How to cite

Preliminary Cost-Effectiveness of Re-Purposing β-Blockers as an Adjunct Treatment for Women with Triple-Negative Breast Cancer — Europe PMC PMID:41302317 — Europe PMC (en), https://europepmc.org/article/MED/41302317 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_5b08efb3fc7b (Metraipolis archive dc_5b08efb3fc7b, sha256 c0481ed5d0bedc63b3e077593cbb1c483032472747af8f0341d1683207d99d84)
BibTeX
@misc{dc5b08efb3fc7b,
  title = {Preliminary Cost-Effectiveness of Re-Purposing β-Blockers as an Adjunct Treatment for Women with Triple-Negative Breast Cancer — Europe PMC PMID:41302317},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41302317},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_5b08efb3fc7b; sha256 c0481ed5d0bedc63b3e077593cbb1c483032472747af8f0341d1683207d99d84},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41302317. Agents can read the archived copy with the MCP tool read_document.